How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

580 results for

Hydatidiform Mole

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

2. Prophylactic chemotherapy for hydatidiform mole to prevent gestational trophoblastic neoplasia. (PubMed)

Prophylactic chemotherapy for hydatidiform mole to prevent gestational trophoblastic neoplasia. This is an update of the original Cochrane Review published in Cochrane Library, Issue 10, 2012.Hydatidiform mole (HM), also called a molar pregnancy, is characterised by an overgrowth of foetal chorionic tissue within the uterus. HMs may be partial (PM) or complete (CM) depending on their gross appearance, histopathology and karyotype. PMs usually have a triploid karyotype, derived from maternal

Full Text available with Trip Pro

2017 Cochrane

3. Differential expression of leukemia inhibitory factor and insulin like growth factor-1 between normal pregnancies, partial hydatidiform moles and complete hydatidiform moles. (PubMed)

Differential expression of leukemia inhibitory factor and insulin like growth factor-1 between normal pregnancies, partial hydatidiform moles and complete hydatidiform moles. Leukemia inhibitory factor (LIF) and insulin like growth factor-1 (IGF-1) are two of the most important growth factors mediating trophoblast actions. We hypothesized that the localization and expression patterns of LIF and IGF-1 in partial and complete hydatidiform moles (HM) compared with normal first trimester placentas (...) on immunostaining intensity.In normal chorionic villi strong expression of LIF and IGF-1 was present. Both LIF and IGF-1 expressions were weaker in the chorionic villi of complete HMs. In complete mole decidua there was a significant decrease in glandular and endothelial IGF-1 expression along with a decrease in decidual cell LIF expression compared to normal first trimester decidua. LIF expression in extravillous trophoblasts was stronger in complete molar placentas compared to normal placentas.LIF and IGF-1

2018 Placenta

4. Accuracy of p57(KIP)(2) compared with genotyping to diagnose complete hydatidiform mole: a systematic review and meta-analysis

Accuracy of p57(KIP)(2) compared with genotyping to diagnose complete hydatidiform mole: a systematic review and meta-analysis Distinguishing hydatidiform moles (HMs) from nonmolar specimens and the subclassification of HM are important because complete hydatidiform mole (CHM) is associated with an increased risk of development of gestational trophoblastic neoplasia. However, diagnosis based solely on morphology has poor inter-observer reproducibility. Recent studies have demonstrated (...) that the use of p57KIP2 immunostaining improves diagnostic accuracy for CHM.To evaluate the accuracy of p57KIP2 immunostaining compared with molecular genotyping for the diagnosis of CHM.Major databases were searched from inception to March 2017 using the terms 'hydatidiform mole', 'p57', and 'genotyping', with their variations, and the search limit for the relevant study design.Any cross-sectional study, case series, case-control study, cohort study, or clinical trial that evaluated the accuracy

Full Text available with Trip Pro

2018 EvidenceUpdates

5. Proteomic identification of predictive biomarkers for malignant transformation in complete hydatidiform moles. (PubMed)

Proteomic identification of predictive biomarkers for malignant transformation in complete hydatidiform moles. Protein expression in cells are associated with oncogenesis. This study aims to explore proteomic profiles and discover potential biomarkers that can predict malignant transformation of hydatidiform mole.Retrospective analysis was done in 14 cases of remission hydatidiform mole and 14 cases of hydatidiform mole who later developed malignancy (GTN group). Molar tissues were retrieved (...) from -70 °C frozen tissue. Subsequently, a large-scale proteomic analysis was performed to identify proteins and compare their abundance levels in the preserved molar tissues from these two groups using a dimethyl-labeling technique coupled with liquid chromatography-tandem mass spectrometry (LC-MS/MS).A total of 2,153 proteins were identified from all samples. 22 and 10 proteins were significantly up-regulated and down-regulated, respectively, in the GTN group compared with the mole group

2019 Placenta

6. p57<sup>KIP</sup><sup>2</sup> immunostaining for diagnosis of hydatidiform mole. (PubMed)

p57KIP2 immunostaining for diagnosis of hydatidiform mole. 29904999 2019 02 28 2019 02 28 1471-0528 125 10 2018 09 BJOG : an international journal of obstetrics and gynaecology BJOG p57 KIP2 immunostaining for diagnosis of hydatidiform mole. 1234 10.1111/1471-0528.15330 Kaur B B North West London Pathology, Hosted by Imperial College Healthcare NHS Trusts, London, WC1N 3JH, UK. Sebire N J NJ Great Ormond Street Hospital, London, WC1N 3JH, UK. eng Journal Article Comment (...) 2018 07 18 England BJOG 100935741 1470-0328 AIM IM BJOG. 2018 Sep;125(10):1226-1233 29782064 Female Genotype Humans Hydatidiform Mole Pregnancy Uterine Neoplasms 2018 6 16 6 0 2019 3 1 6 0 2018 6 16 6 0 ppublish 29904999 10.1111/1471-0528.15330

2018 BJOG

7. Temporal trends in incidence and outcome of hydatidiform mole: a retrospective cohort study. (PubMed)

Temporal trends in incidence and outcome of hydatidiform mole: a retrospective cohort study. Reported incidence rates of hydatidiform mole (HM) show wide geographic and temporal variations, making reliable international comparisons difficult. The aim of the current study was to examine temporal trends in the incidence of HM and post-molar gestational trophoblastic neoplasia (GTN) in Stockholm County.Data of all women with a diagnosis of HM in Stockholm County 1991-2010 was collected (...) . The incidence of HM was assessed both in relation to number of births and viable conceptions (births and pregnancy terminations). The risk of post-molar GTN was analysed for all HM, as well as for the subtypes complete (CHM) and partial hydatidiform mole (PHM). Temporal trends were analysed by stratifying the study period into five-year intervals.The overall incidence rate of HM was 2.08/1000 deliveries and 1.48/1000 viable conceptions. A significant temporal increase in the incidence rate of HM, as well

Full Text available with Trip Pro

2018 Acta Oncologica

8. New insights in the pathophysiology of complete hydatidiform mole. (PubMed)

New insights in the pathophysiology of complete hydatidiform mole. The majority of complete hydatidiform moles (CHM) are detected on ultrasound examination by the end of the first trimester when they present as multiple sonolucent cysts. To better understand the pathophysiology of this unique placental pathology and improve its prenatal diagnosis and management we have reviewed the ultrasound features of CHM before the appearance of cystic changes.We searched our database to identify all women (...) diagnosed with a complete hydatidiform mole confirmed by histopathology who had an ultrasound examination before 9 weeks' gestation. We reviewed their ultrasound reports and all the corresponding images.The study group included 39 women with a positive pregnancy test and vaginal bleeding, 36 of whom had at least two ultrasound examinations before 9 weeks' gestation. At the first scan (mean gestation age 7 + 1 weeks; SD 1.1), 29 out 39 (74.4%) of CHM presented as a heterogeneous hyperechogenic mass

Full Text available with Trip Pro

2018 Placenta

9. Is Ki-67 of Diagnostic Value in Distinguishing Between Partial and Complete Hydatidiform Moles? A Systematic Review and Meta-analysis.

Is Ki-67 of Diagnostic Value in Distinguishing Between Partial and Complete Hydatidiform Moles? A Systematic Review and Meta-analysis. To demonstrate the value of Ki-67 in distinguishing between partial and complete hydatidiform moles.We searched electronic databases included Medline, WOK, Cochrane Library and CNKI, through January 24, 2015. Experts were consulted, and references from related articles were examined. The meta-analysis was conducted with RevMan5.3, according to the PRISMA (...) guidelines. Mantel-Haenszel estimates were calculated and pooled under a random effect model, with data expressed as odds ratio (OR) and 95% confidence interval (CI).We analyzed eight trials with a total of 337 participants who underwent uterine curettage and met the inclusion criteria. A significantly higher expression of Ki-67 was observed in complete than in partial hydatidiform moles (OR=3.28; 95%CI=1.80-5.96; p<0.0001).The Ki-67 expression was higher in complete than in partial hydatidiform moles

2018 Anticancer research

10. Prevalence and Factors Associated with Hydatidiform Mole among Patients Undergoing Uterine Evacuation at Mbarara Regional Referral Hospital (PubMed)

Prevalence and Factors Associated with Hydatidiform Mole among Patients Undergoing Uterine Evacuation at Mbarara Regional Referral Hospital We sought to determine the prevalence of and factors associated with hydatidiform molar gestations amongst patients undergoing uterine evacuation at Mbarara Regional Referral Hospital (MRRH), Mbarara, Uganda.This was a cross-sectional study carried out from November 2016 to February 2017. All patients admitted for uterine evacuation for nonviable pregnancy (...) were included. The study registered 181 patients. Data were collected on sociodemographics, medical conditions, obstetrics, and gynecological factors. The evacuated tissue received a full gross and histopathologic examination. Cases of pathologically suspected complete hydatidiform mole were confirmed by p57 immunohistochemistry. Data were analyzed using STATA 13.The prevalence of hydatidiform mole was 6.1% (11/181). All detected moles were complete hydatidiform moles, and there were no diagnosed

Full Text available with Trip Pro

2018 Obstetrics and gynecology international

11. Invasive hydatidiform mole in the cervix (PubMed)

Invasive hydatidiform mole in the cervix 29875909 2018 07 24 1937-8688 29 2018 The Pan African medical journal Pan Afr Med J Invasive hydatidiform mole in the cervix. 27 10.11604/pamj.2018.29.27.10675 Boufettal Houssine H Centre Hospitalier Universitaire Ibn Rochd, Faculté de Médecine et Pharmacie, Hassan II University of Casablanca, Casablanca, Maroc. Samouh Naïma N Centre Hospitalier Universitaire Ibn Rochd, Faculté de Médecine et Pharmacie, Hassan II University of Casablanca, Casablanca (...) , Maroc. eng Journal Article 2018 01 12 Uganda Pan Afr Med J 101517926 Invasive mole cervix chemotherapy gestational trophoblastic tumor 2016 09 05 2016 10 31 2018 6 8 6 0 2018 6 8 6 0 2018 6 8 6 1 epublish 29875909 10.11604/pamj.2018.29.27.10675 PAMJ-29-27 PMC5987108

Full Text available with Trip Pro

2018 The Pan African medical journal

12. Hydatidiform mole: validity of the registration in the Danish National Patient Registry, the Danish Cancer Registry, and the Danish Pathology Registry 1999–2009 (PubMed)

Hydatidiform mole: validity of the registration in the Danish National Patient Registry, the Danish Cancer Registry, and the Danish Pathology Registry 1999–2009 To examine the validity of registration of hydatidiform mole (HM) in the Danish National Patient Registry (NPR), the Danish Cancer Registry (DCR), and the Danish Pathology Registry (DPR).We selected women registered with a first-time HM code in NPR, DCR, and DPR from 1999 to 2009. We found most women registered in DPR. For a random

Full Text available with Trip Pro

2018 Clinical epidemiology

13. Causative Mutations and Mechanism of Androgenetic Hydatidiform Moles. (PubMed)

Causative Mutations and Mechanism of Androgenetic Hydatidiform Moles. Androgenetic complete hydatidiform moles are human pregnancies with no embryos and affect 1 in every 1,400 pregnancies. They have mostly androgenetic monospermic genomes with all the chromosomes originating from a haploid sperm and no maternal chromosomes. Androgenetic complete hydatidiform moles were described in 1977, but how they occur has remained an open question. We identified bi-allelic deleterious mutations in MEI1 (...) , TOP6BL/C11orf80, and REC114, with roles in meiotic double-strand breaks formation in women with recurrent androgenetic complete hydatidiform moles. We investigated the occurrence of androgenesis in Mei1-deficient female mice and discovered that 8% of their oocytes lose all their chromosomes by extruding them with the spindles into the first polar body. We demonstrate that Mei1-/- oocytes are capable of fertilization and 5% produce androgenetic zygotes. Thus, we uncover a meiotic abnormality

2018 American Journal of Human Genetics

14. A 34-Week Size Uterus with a Complete Hydatidiform Mole: Hook Effect and Severe Anemia with No Vaginal Bleeding (PubMed)

A 34-Week Size Uterus with a Complete Hydatidiform Mole: Hook Effect and Severe Anemia with No Vaginal Bleeding Complete hydatidiform mole is an abnormal pregnancy that usually presents with vaginal bleeding and markedly elevated serum ß-hCG levels. We report a rare case of complete hydatidiform mole occurring in a 16-year-old nulligravid who presented with a 34-week size uterus and a relatively low serum ß-hCG level (722 IU/L)-likely related to the "hook effect"-and severe anemia (hemoglobin (...) : 6.1 g/dL) despite the absence of vaginal bleeding. She also reported right flank pain and was diagnosed with moderate right hydronephrosis owing to the compression exerted by the enlarged uterus on the right ureter. The patient received a total of 6 units of packed red blood cells and was managed by dilation and evacuation followed by serial monitoring of serum ß-hCG levels. Therefore, complete mole can present with symptoms related to an enlarged uterus and severe anemia before the occurrence

Full Text available with Trip Pro

2018 Case reports in obstetrics and gynecology

15. Ultrasound and MRI Findings of Twin Pregnancies with Complete Hydatidiform Mole and Coexisting Normal Fetus: Two Case Reports (PubMed)

Ultrasound and MRI Findings of Twin Pregnancies with Complete Hydatidiform Mole and Coexisting Normal Fetus: Two Case Reports Both twin pregnancies with complete hydatidiform mole and coexisting normal fetus (CHMCF) and partial hydatidiform mole can be found in association with a live fetus and a placenta displaying a molar degeneration. Two cases of CHMCF using magnetic resonance imaging (MRI) for a diagnosis are reported.In the first, CHMCF was suspected at 12 weeks of gestation. At 18 weeks (...) during the 1 year-follow up period. Pathological examination in both cases was consistent with a complete hydration mole and a coexisting normal female fetus.MRI was useful for an accurate diagnosis for CHMCF.

Full Text available with Trip Pro

2018 Kobe Journal of Medical Sciences

16. A bioinformatics transcriptome meta-analysis highlights the importance of trophoblast differentiation in the pathology of hydatidiform moles. (PubMed)

A bioinformatics transcriptome meta-analysis highlights the importance of trophoblast differentiation in the pathology of hydatidiform moles. Hydatidiform mole (HM) is an aberrant human pregnancy with abnormal trophoblastic development, migration/invasion of the extravillous trophoblast in the decidua. These abnormalities are established in a hypoxic environment during the first trimester of gestation.Using text mining, we identified 72 unique genes that are linked to HM (HM-linked genes

2018 Placenta

17. Biallelic PADI6 variants linking infertility, miscarriages, and hydatidiform moles. (PubMed)

Biallelic PADI6 variants linking infertility, miscarriages, and hydatidiform moles. Recurrent hydatidiform moles (RHM) are aberrant human pregnancies characterized by absence of, or abnormal, embryonic development, hydropic degeneration of chorionic villi, and hyperproliferation of the trophoblast. Biallelic mutations in two maternal-effect genes, NLRP7 and KHDC3L, underlie the causation of RHM in 60% of patients. We performed exome sequencing on a patient with six pregnancy losses, two

2018 European Journal of Human Genetics

18. Comparison of different therapeutic strategies for complete hydatidiform mole in women at least 40 years old: a retrospective cohort study. (PubMed)

Comparison of different therapeutic strategies for complete hydatidiform mole in women at least 40 years old: a retrospective cohort study. There are three main therapeutic strategies, namely expectant management (dilation and curettage only), prophylactic chemotherapy and prophylactic total hysterectomy for treating older women with complete hydatidiform mole (CHM). However, the scientific community has so far, not unanimously accepted the above-mentioned methods. The objective of this study

Full Text available with Trip Pro

2017 BMC Cancer

19. A twin pregnancy with a hydatidiform mole and a coexisting live fetus: prenatal diagnosis, treatment, and follow-up (PubMed)

A twin pregnancy with a hydatidiform mole and a coexisting live fetus: prenatal diagnosis, treatment, and follow-up Twin molar pregnancy with a hydatidiform mole and a coexisting live fetus is a rare form of gestational trophoblastic disease associated with an increased risk of obstetric complications and poor perinatal outcome. Prenatal diagnosis is essential for couple counseling and follow-up in Tertiary Reference Centers. Magnetic resonance imaging is important for the diagnostic (...) differentiation of placental mesenchymal dysplasia and exclusion of myometrial invasion. Here we present a case of twin molar pregnancy with a hydatidiform mole and a coexisting live fetus diagnosed at gestational week 14 using two-dimensional (2D) and three-dimensional (3D) ultrasound and magnetic resonance imaging. We also describe the obstetric management and postmolar follow-up.

Full Text available with Trip Pro

2017 Journal of Ultrasonography

20. F10, a novel hydatidiform mole-associated gene, inhibits the paclitaxel sensitivity of A549 lung cancer cells by downregulating BAX and caspase-3 (PubMed)

F10, a novel hydatidiform mole-associated gene, inhibits the paclitaxel sensitivity of A549 lung cancer cells by downregulating BAX and caspase-3 F10 is a novel hydatidiform mole (HM)-associated gene that was initially identified during a study into the pathogenesis of HMs. However, the role of the F10 gene requires further investigation. Our, previous studies have indicated that F10 may be involved in the malignant transformation of HMs and the development of certain types of adenocarcinoma

Full Text available with Trip Pro

2017 Oncology letters

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>